BRISTOL MYERS SQUIBB CO
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 12, 2025
BMY$62.140.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SUMMARY OF ABBREVIATED TERMS
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this 2024 Form 10-K, unless the context otherwise indicates. Throughout this 2024 Form 10-K, we have used terms which are defined below:
| 2024 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2024 | MAA | Marketing Authorization Application |
|---|---|---|---|
| 2021 Plan | 2021 Stock Award and Incentive Plan | MCL | mantle cell lymphoma |
| 2seventy bio | 2seventy bio, Inc. | MCO | Managed Care Organization |
| 340B Program | 340B Drug Pricing Program | MDS | myelodysplastic syndromes |
| 2024 Senior Unsecured Notes | Aggregate principal amount of $13.0 billion of unsecured senior notes issued by BMS in February 2024 | Merck | Merck & Co., Inc. |
| AbbVie | AbbVie Inc. | MF | myelofibrosis |
| ADC | antibody-drug conjugate | Mirati | Mirati Therapeutics, Inc. |
| aGVHD | acute graft-versus-host disease | MPM | Malignant Pleural Mesothelioma |
| Amgen | Amgen Inc. | MS | Multiple Sclerosis |
| Amylin | Amylin Pharmaceuticals, Inc. | MSI-High | microsatellite instability-high |
| ANDA | abbreviated New Drug Application | MyoKardia | MyoKardia, Inc. |
| ASC | Accounting Standards Codification | NAV | net asset value |
| ASR | Accelerated Share Repurchase | NDA | New Drug Application |
| AstraZeneca | AstraZeneca PLC | Nimbus | Nimbus Therapeutics, LLC |
| BCMA | B-cell maturation antigen | NKT | natural killer T |
| Biogen | Biogen, Inc. | Novartis | Novartis Pharmaceutical Corporation |
| Biohaven | Biohaven Pharmaceutical Holding Company Ltd. | NSCLC | non-small cell lung cancer |
| BLA | Biologics License Application | NVAF | non-valvular atrial fibrillation |
| CAR-T | Chimeric Antigen Receptor T cells | OCE | Oncology Center of Excellence |
| Celgene | Celgene Corporation acquired by BMS on November 20, 2019 | OECD | Organization for Economic Co-operation and Development |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | oHCM | obstructive hypertrophic cardiomyopathy |
| CGDP | Coverage Gap Discount Program | OIG | Office of Inspector General of the U.S. Department of Health and Human Services |
| cGMP | current Good Manufacturing Practices | Ono | Ono Pharmaceutical Co., Ltd. |
| Cheplapharm | Cheplapharm Arzneimittel GmbH | Orum | Orum Therapeutics |
| CHMP | Committee for Medicinal Products for Human Use | Otsuka | Otsuka Pharmaceutical Co., Ltd. |
| CLL | Chronic lymphocytic leukemia | PBMs | Pharmacy Benefit Managers |
| CML | chronic myeloid leukemia | PCAOB | Public Company Accounting Oversight Board |
| COSO | Committee of Sponsoring Organizations of the Treadway Commission | PD-1 | programmed death receptor-1 |
| CRC | colorectal carcinoma | PDMA | Prescription Drug Marketing Act |
| DLBCL | diffuse large B-cell lymphoma | PDUFA | Prescription Drug User Fee Act |
| Dragonfly | Dragonfly Therapeutics, Inc. | Pfizer | Pfizer, Inc. |
| DSA | Distribution Services Agreement | PhRMA Code | Pharmaceutical Research and Manufacturers of America’s Professional Practices Code |
| EC | European Commission | PPF | progressive pulmonary fibrosis |
| EGFR | estimated glomerular filtration rate | Prothena | Prothena Corporation |
| Eisai | Eisai Co., Ltd. | PRP | potentially responsible party |
| EMA | European Medicines Agency | PsA | psoriatic arthritis |
| EPS | earnings per share | PTR | patent term restoration |
| ESA | erythoropoiesis-stimulating agent | R&D | research and development |
| EU | except as otherwise noted, EU refers to the countries that are members of the European Union plus the United Kingdom | RA | rheumatoid arthritis |
| Evotec | Evotec SE | RayzeBio | RayzeBio, Inc. |
| Exchange Act | the Securities Exchange Act o 1934 | RCC | renal cell carcinoma |
| FASB | Financial Accounting Standards Board | RDP | Regulatory Data Protection |
| FDA | U.S. Food and Drug Administration | REMS | Risk Evaluation and Mitigation Strategy |
| FL | follicular lymphoma | Roche | Roche Holding AG |
| GAAP | U.S. generally accepted accounting principles | ROS1 | c-ros oncogene 1 |
| Gilead | Gilead Sciences, Inc. | RS | ring sideroblast |
| GILTI | global intangible low taxed income | Sanofi | Sanofi S.A. |
| GlaxoSmithKline | GlaxoSmithKline PLC | SEC | U.S. Securities and Exchange Commission |
| GTN | gross-to-net | SLE | systemic lupus erythematosus |
| Halozyme | Halozyme Therapeutics, Inc. | SLL | small lymphocytic lymphoma |
| HCC | hepatocellular carcinoma | SOFR | Secured Overnight Financing Rate |
| HCM | hypertrophic cardiomyopathy | SPC | Supplementary Protection Certificate |
| IMDC | International Metastatic Renal Cell Carcinoma Database Consortium | SystImmune | SystImmune, Inc. |
| Immatics | Immatics N.V. | Takeda | Takeda Pharmaceutical Company Limited |
| IO | immuno-oncology | TCJA | the Tax Cuts and Jobs Act of 2017 |
| IPF | idiopathic pulmonary fibrosis | Turning Point | Turning Point Therapeutics, Inc. |
| IPRD | in-process research and development | UC | ulcerative colitis |
| IRA | Inflation Reduction Act of 2022 | UK | United Kingdom |
| IRS | Internal Revenue Services | U.S. | United States |
| JIA | Juvenile Idiopathic Arthritis | VAT | value added tax |
| Karuna | Karuna Therapeutics, Inc. | WTO | World Trade Organization |
| LBCL | large B-cell lymphoma | ||
| Lilly | Eli Lilly and Company | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.